Benign prostatic hyperplasia

Audience: Patients and providers
Status: Clinical guide · patient + provider
Last updated: 2026-03-27

1. Clinical overview

Benign prostatic hyperplasia is nonmalignant prostate enlargement associated with lower urinary tract symptoms, bladder outlet obstruction risk, and meaningful quality-of-life burden in older men.

2. Common causes and risk factors

• Age-related prostatic enlargement is the core driver.
• Larger prostate volume, metabolic disease, obesity, and certain medications can worsen symptoms.

3. Typical symptoms

• Hesitancy, weak stream, incomplete emptying, frequency, urgency, nocturia, and post-void dribbling.

4. Diagnosis and evaluation

• Clarify storage versus voiding symptoms, severity, bother, and symptom trajectory.
• Screen for retention, hematuria, recurrent UTI, renal dysfunction, and alternative causes such as prostatitis or malignancy.
• Review medication contributors such as anticholinergics, decongestants, and opioids.

5. Treatment (non-pharmacologic)

• Fluid timing adjustment, caffeine/alcohol reduction, timed voiding, and constipation management.
• Shared decision-making is appropriate for mild symptoms with low bother.

6. Treatment (pharmacologic)

• Alpha-1 blockers such as tamsulosin, alfuzosin, silodosin, doxazosin, or terazosin often improve flow relatively quickly.
• 5-alpha reductase inhibitors such as finasteride or dutasteride are more useful when prostate enlargement is present and long-term reduction is the goal.
• Tadalafil can help selected patients, and combination therapy such as tamsulosin plus finasteride is common in more symptomatic enlarged-prostate disease.

7. Monitoring and follow-up

• Track symptom score trajectory, nocturia burden, orthostasis risk, and retention symptoms.
• Reassess response within weeks for alpha-blocker starts and over months for prostate-size directed therapy.

8. Practical counseling points

• Warn patients about dizziness and orthostasis with alpha blockers.
• Explain that 5-alpha reductase inhibitor benefit is gradual, not immediate.
• Escalate quickly for inability to void, fever, or gross hematuria.

9. Red flags and escalation

• Urinary retention, recurrent infection, renal impairment, bladder stones, or persistent hematuria require prompt evaluation.
• Refer to urology when symptoms are severe, refractory, or procedurally actionable.

10. Guideline references

• American Urological Association BPH guideline.
• EAU lower urinary tract symptom guidance.
• Beers criteria considerations for older adults and anticholinergic burden.

Note: Educational guide only; not a substitute for individualized medical care.